Baidu
map

肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

2020 ISL共识文件：外周淋巴水肿的诊断和治疗

2020-03-01 国际淋巴学协会International Society of Lymphology Lymphology. 2020;53(1):3-19.

淋巴水肿

2020年，国际淋巴学学会(ISL)发布了外周淋巴水肿的诊断和治疗共识文件。文章主要内容涉及淋巴水肿的分期，外周淋巴水肿的诊断以及治疗。

中文标题：

2020 ISL共识文件：外周淋巴水肿的诊断和治疗

英文标题：

The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology.

发布机构：

国际淋巴学协会International Society of Lymphology

发布日期：

2020-03-01

简要介绍：

2020年，国际淋巴学学会(ISL)发布了外周淋巴水肿的诊断和治疗共识文件。文章主要内容涉及淋巴水肿的分期，外周淋巴水肿的诊断以及治疗。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020+ISL共识文件：外周淋巴水肿的诊断和治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d0ca91c0019211d5, title=2020 ISL共识文件：外周淋巴水肿的诊断和治疗, enTitle=The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology., guiderFrom=Lymphology. 2020;53(1):3-19., authorId=0, author=, summary=2020年，国际淋巴学学会(ISL)发布了外周淋巴水肿的诊断和治疗共识文件。文章主要内容涉及淋巴水肿的分期，外周淋巴水肿的诊断以及治疗。, cover=https://img.medsci.cn/2020618/1592490813457_2020535.jpg, journalId=0, articlesId=null, associationId=1904, associationName=国际淋巴学协会International Society of Lymphology, associationIntro=International Society of Lymphology, copyright=0, guiderPublishedTime=Sun Mar 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年，国际淋巴学学会(ISL)发布了外周淋巴水肿的诊断和治疗共识文件。文章主要内容涉及淋巴水肿的分期，外周淋巴水肿的诊断以及治疗。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=10118, tagName=淋巴水肿)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=10118, guiderKeyword=淋巴水肿, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12054, appHits=245, showAppHits=0, pcHits=2037, showPcHits=11809, likes=0, shares=26, comments=5, approvalStatus=1, publishedTime=Thu Jun 18 23:12:59 CST 2020, publishedTimeString=2020-03-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Thu Jun 18 22:34:26 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 22:16:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020+ISL共识文件：外周淋巴水肿的诊断和治疗.pdf)])
2020+ISL共识文件：外周淋巴水肿的诊断和治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1242472, encodeId=3edd12424e250, content=内容非常有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d43d4374414, createdName=140649a6m27暂无昵称, createdTime=Thu Sep 01 13:01:37 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204394, encodeId=ac5e12043946c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=577d5131198, createdName=146579e3m35暂无昵称, createdTime=Sun Mar 20 18:30:53 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014695, encodeId=15ae1014695b7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 08:03:01 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945836, encodeId=4d9494583683, content=没有翻译版本的-, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKAN9WI6xiacTaJ5SEjwibqB5yv1uLd1BzicQMmr2VeHlaM5FejqYAUNLkAFSZLh0SiaceqVaKA7QY0Kw/132, createdBy=894d5329967, createdName=医者8526, createdTime=Fri Mar 05 21:20:30 CST 2021, time=2021-03-05, status=1, ipAttribution=)]
    2022-09-01 140649a6m27暂无昵称

    内容非常有用。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1242472, encodeId=3edd12424e250, content=内容非常有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d43d4374414, createdName=140649a6m27暂无昵称, createdTime=Thu Sep 01 13:01:37 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204394, encodeId=ac5e12043946c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=577d5131198, createdName=146579e3m35暂无昵称, createdTime=Sun Mar 20 18:30:53 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014695, encodeId=15ae1014695b7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 08:03:01 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945836, encodeId=4d9494583683, content=没有翻译版本的-, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKAN9WI6xiacTaJ5SEjwibqB5yv1uLd1BzicQMmr2VeHlaM5FejqYAUNLkAFSZLh0SiaceqVaKA7QY0Kw/132, createdBy=894d5329967, createdName=医者8526, createdTime=Fri Mar 05 21:20:30 CST 2021, time=2021-03-05, status=1, ipAttribution=)]
    2022-03-20 146579e3m35暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1242472, encodeId=3edd12424e250, content=内容非常有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d43d4374414, createdName=140649a6m27暂无昵称, createdTime=Thu Sep 01 13:01:37 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204394, encodeId=ac5e12043946c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=577d5131198, createdName=146579e3m35暂无昵称, createdTime=Sun Mar 20 18:30:53 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014695, encodeId=15ae1014695b7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 08:03:01 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945836, encodeId=4d9494583683, content=没有翻译版本的-, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKAN9WI6xiacTaJ5SEjwibqB5yv1uLd1BzicQMmr2VeHlaM5FejqYAUNLkAFSZLh0SiaceqVaKA7QY0Kw/132, createdBy=894d5329967, createdName=医者8526, createdTime=Fri Mar 05 21:20:30 CST 2021, time=2021-03-05, status=1, ipAttribution=)]
    2021-09-05 pyunzhen

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1242472, encodeId=3edd12424e250, content=内容非常有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d43d4374414, createdName=140649a6m27暂无昵称, createdTime=Thu Sep 01 13:01:37 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204394, encodeId=ac5e12043946c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=577d5131198, createdName=146579e3m35暂无昵称, createdTime=Sun Mar 20 18:30:53 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014695, encodeId=15ae1014695b7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f54689743, createdName=pyunzhen, createdTime=Sun Sep 05 08:03:01 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945836, encodeId=4d9494583683, content=没有翻译版本的-, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKAN9WI6xiacTaJ5SEjwibqB5yv1uLd1BzicQMmr2VeHlaM5FejqYAUNLkAFSZLh0SiaceqVaKA7QY0Kw/132, createdBy=894d5329967, createdName=医者8526, createdTime=Fri Mar 05 21:20:30 CST 2021, time=2021-03-05, status=1, ipAttribution=)]
    2021-03-05 医者8526

    没有翻译版本的-

    0

拓展阅读

2022 AVF/AVLS/SVM专家共识：淋巴水肿的诊断和治疗

美国静脉联盟(AVF,American Venous Forum) · 2022-03-08

2022 国际共识：乳腺癌相关淋巴水肿的多学科预防干预

暂未更新 · 2022-09-16

2022 AVLS的立场声明：为淋巴水肿患者选择适当的压迫

美国静脉和淋巴协会（American Vein and Lymphatic Society，AVLS) · 2023-01-06

乳腺癌术后相关淋巴水肿危险因素的最佳证据总结

暂未更新 · 2023-10-30

2024 NICE 介入操作指南：腋窝或腹股沟淋巴结清扫时淋巴静脉吻合预防继发性淋巴水肿 [IPG785]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-04-16

Baidu
map
Baidu
map
Baidu
map